Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRI NASDAQ:BXRX NASDAQ:CING NASDAQ:CMRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$1.04+3.0%$0.93$0.54▼$2.22$10.24M0.53101,237 shs38,321 shsBXRXBaudax Bio$0.02$0.02$0.01▼$3.47$1.14M1.57281,029 shs310,872 shsCINGCingulate$4.35+3.3%$4.05$3.02▼$6.01$22.79M-0.75160,823 shs144,703 shsCMRAComera Life Sciences$0.00$0.00▼$0.03$3K1.185,524 shsN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera+2.97%0.00%+21.18%+20.93%+25.24%BXRXBaudax Bio0.00%0.00%0.00%0.00%0.00%CINGCingulate+3.33%+7.14%+12.69%0.00%+0.23%CMRAComera Life Sciences0.00%0.00%-50.00%-50.00%-99.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$1.04+3.0%$0.93$0.54▼$2.22$10.24M0.53101,237 shs38,321 shsBXRXBaudax Bio$0.02$0.02$0.01▼$3.47$1.14M1.57281,029 shs310,872 shsCINGCingulate$4.35+3.3%$4.05$3.02▼$6.01$22.79M-0.75160,823 shs144,703 shsCMRAComera Life Sciences$0.00$0.00▼$0.03$3K1.185,524 shsN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera+2.97%0.00%+21.18%+20.93%+25.24%BXRXBaudax Bio0.00%0.00%0.00%0.00%0.00%CINGCingulate+3.33%+7.14%+12.69%0.00%+0.23%CMRAComera Life Sciences0.00%0.00%-50.00%-50.00%-99.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera 2.00Hold$2.75164.42% UpsideBXRXBaudax Bio 0.00N/AN/AN/ACINGCingulate 2.67Moderate Buy$26.25503.45% UpsideCMRAComera Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CING, BXRX, BFRI, and CMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025BFRIBiofronteraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CINGCingulateWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025BFRIBiofronteraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CINGCingulateWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/22/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$61.00 ➝ $62.008/8/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$37.32M0.28N/AN/A$0.57 per share1.82BXRXBaudax Bio$1.27M0.90N/AN/A($14.93) per share0.00CINGCingulateN/AN/AN/AN/A$2.32 per shareN/ACMRAComera Life Sciences$1.00M0.00N/AN/AN/ANaNCompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$17.76M-$2.26N/AN/AN/A-42.34%-1,104.09%-82.28%11/12/2025 (Estimated)BXRXBaudax Bio-$58.79M-$9.23N/AN/AN/AN/AN/A-175.11%N/ACINGCingulate-$15.55M-$4.10N/AN/AN/AN/A-232.16%-132.07%11/6/2025 (Estimated)CMRAComera Life Sciences-$18MN/A0.00N/AN/AN/AN/AN/AN/ALatest CING, BXRX, BFRI, and CMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025CINGCingulate-$0.82N/AN/AN/AN/AN/A8/19/2025Q2 2025CINGCingulate-$0.82-$1.09-$0.27-$1.09N/AN/A8/13/2025Q2 2025BFRIBiofrontera-$0.45-$0.57-$0.12-$0.57$8.30 million$9.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/ABXRXBaudax BioN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/ACMRAComera Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofrontera8.990.960.75BXRXBaudax BioN/A0.070.07CINGCingulateN/A1.521.52CMRAComera Life SciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%BXRXBaudax Bio9.05%CINGCingulate41.31%CMRAComera Life SciencesN/AInsider OwnershipCompanyInsider OwnershipBFRIBiofrontera4.80%BXRXBaudax Bio0.10%CINGCingulate4.04%CMRAComera Life Sciences8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera7010.14 million9.65 millionNo DataBXRXBaudax Bio952.46 million52.41 millionNot OptionableCINGCingulate205.41 million5.19 millionNot OptionableCMRAComera Life Sciences230.74 million28.00 millionNot OptionableCING, BXRX, BFRI, and CMRA HeadlinesRecent News About These CompaniesAnalyzing Comera Life Sciences (NASDAQ:CMRA) and AEON Biopharma (NASDAQ:AEON)October 5, 2025 | americanbankingnews.comTandy Leather Factory (NASDAQ:TLF) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comCarisma Therapeutics to Join Citizens JMP Life Sciences ConferenceMay 12, 2024 | msn.comComera Life Sciences Announces Sweeping Workforce TerminationJanuary 31, 2024 | msn.comComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionJanuary 4, 2024 | finance.yahoo.comComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionJanuary 4, 2024 | finance.yahoo.comComera Life Sciences to explore strategic alternativesDecember 6, 2023 | msn.comComera Life Sciences Announces Process Exploring Strategic AlternativesDecember 6, 2023 | finance.yahoo.comComera Life Sciences Stock (NASDAQ:CMRA), Analyst Ratings, Price Targets, PredictionsNovember 26, 2023 | benzinga.comComera Life Sciences Holdings Inc [CMRA] stock for 1,049,897 USD was acquired by Cherington CharlesNovember 17, 2023 | knoxdaily.comKComera Life Sciences Designates Dorothy Clarke to Board of DirectorsNovember 13, 2023 | finance.yahoo.comComera Life Sciences Appoints Dorothy Clarke to Board of DirectorsNovember 13, 2023 | finance.yahoo.comComera Life Sciences GAAP EPS of -$0.10, revenue of $0.14MNovember 9, 2023 | msn.comComera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business HighlightsNovember 9, 2023 | finance.yahoo.comComera Life Sciences Holdings Inc [CMRA] Insider Activity: An Update for InvestorsNovember 8, 2023 | knoxdaily.comKInvesting in Comera Life Sciences Holdings Inc (CMRA): What You Must KnowOctober 18, 2023 | knoxdaily.comKComera Life Sciences Advancing Subcutaneous Monoclonal Antibody FormulationsOctober 18, 2023 | finance.yahoo.comComera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery ConferenceOctober 16, 2023 | finance.yahoo.comComera Life Sciences Holdings Inc [CMRA] 10% Owner makes an insider purchase of 2,053,789 shares worth 1.05 million.October 13, 2023 | knoxdaily.comKMassive Insider Trade At Comera Life SciencesSeptember 13, 2023 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAfter the Fed's Rate Cut, PNC Could See a Mortgage Refinance BoomBy Jordan Chussler | September 21, 2025Carmax: Now is the Time to Load Up On This Used Car StockBy Thomas Hughes | September 26, 2025Rocket Lab’s Bullish Case Remains Intact Despite Recent OfferingBy Ryan Hasson | September 24, 2025McDonald’s: New All-Time Highs Are InevitableBy Thomas Hughes | September 19, 2025Why Affirm Could Be the Next Big Winner in Rate-Cut RallyBy Gabriel Osorio-Mazilli | September 26, 2025CING, BXRX, BFRI, and CMRA Company DescriptionsBiofrontera NASDAQ:BFRI$1.04 +0.03 (+2.97%) Closing price 10/9/2025 03:59 PM EasternExtended Trading$1.02 -0.02 (-1.83%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Baudax Bio NASDAQ:BXRXBaudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.Cingulate NASDAQ:CING$4.35 +0.14 (+3.33%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$4.38 +0.03 (+0.69%) As of 04:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Comera Life Sciences NASDAQ:CMRAComera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
